Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health
03 Mai 2024 - 4:07PM
Business Wire
– TIME recognizes Dr. Mendell’s decades-long contributions in
the treatment of neuromuscular disease and the advancement of gene
therapy, including the first gene therapy for Duchenne muscular
dystrophy
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in
precision genetic medicine for rare diseases, today announced that
TIME named renown neuromuscular researcher, physician and gene
therapy pioneer Jerry R. Mendell, M.D., to the inaugural 2024
TIME100 Health, a list of 100 individuals who most influenced
global health this year. Dr. Mendell was recognized for his
lifetime commitment to neuromuscular disease and achievements in
genetic medicine that propelled a new age of treatment for several
genetic diseases, including Duchenne muscular dystrophy.
The TIME100 Health list recognizes the impact, innovation, and
achievement of the world’s most influential individuals in health.
TIME selected a community of leaders across industries dedicated to
creating tangible and credible change for a healthier population,
including pioneering scientists who are steering the evolution of
global health in 2024.
“Dr. Mendell’s humility and compassion for patients and families
shines through his relentless focus on advancing science with the
potential to change the course of devastating, fatal and once
untreatable neuromuscular diseases,” said Louise Rodino-Klapac,
Ph.D., executive vice president, head of R&D and chief
scientific officer, Sarepta Therapeutics. “I have had the honor of
working with Dr. Mendell for many years, first at Nationwide
Children’s Hospital and now at Sarepta, to see some of his life’s
work come to fruition. Dr. Mendell’s accomplishments in the field
of neuromuscular disease, and the care that he provided to patients
and their families in more than 50 years of practice, continue to
inspire Sarepta and others working to advance the science of
genetic medicine.”
Dr. Mendell began his career at the U.S. National Institutes of
Health, and shortly after he met his first patient living with
Duchenne. His early work was followed by decades as a clinician and
researcher at Nationwide Children’s Hospital to understand
Duchenne’s progressive muscle wasting trajectory and ways to
intervene to slow or alter the course of the disease. He is a
pioneer in gene therapy for neuromuscular diseases, including
spinal muscular atrophy (SMA), and during his tenure at Nationwide
Children’s served as an investigator for multiple clinical trials,
including those for Duchenne and limb-girdle muscular dystrophies
(LGMDs). Dr. Mendell recently retired from his clinical and
research role at Nationwide Children’s and is now serving as an
advisor to Sarepta and to the Center for Gene Therapy in the
Abigail Wexner Research Institute at Nationwide Children’s.
In addition to recognition on the TIME100 Health list, Dr.
Mendell is a 2024 recipient of the King Faisal Prize Laureate in
Medicine. In 2021, he was elected to the National Academy of
Medicine and was the first recipient of the American Society for
Gene and Cell Therapy (ASGCT)’s Jerry Mendell Translational
Medicine Award. He is also a published author of more than 400
peer-reviewed articles and books about skeletal muscle disease,
peripheral nerve disorders and gene therapy.
About Sarepta Therapeutics Sarepta is on an urgent
mission: engineer precision genetic medicine for rare diseases that
devastate lives and cut futures short. We hold leadership positions
in Duchenne muscular dystrophy (DMD) and limb-girdle muscular
dystrophies (LGMDs), and we currently have more than 40 programs in
various stages of development. Our vast pipeline is driven by our
multi-platform Precision Genetic Medicine Engine in gene therapy,
RNA and gene editing. For more information, please visit
www.sarepta.com or follow us on LinkedIn, X (formerly Twitter),
Instagram and Facebook.
Internet Posting of Information We routinely post
information that may be important to investors in the 'For
Investors' section of our website at www.sarepta.com. We encourage
investors and potential investors to consult our website regularly
for important information about us.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240503391992/en/
Investor Contact: Ian Estepan, 617-274-4052
iestepan@sarepta.com
Media Contact: Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com
Sarepta Therapeutics (NASDAQ:SRPT)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Sarepta Therapeutics (NASDAQ:SRPT)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024